IL17A and inflammatory bowel disease: Importantly, in a double-blinded clinical trials, targeting IL-17A or IL-17R was ineffective to treat Crohn’s disease, rendering higher risk of adverse events, indicating a protective role of IL-17A in colitis studies (12, 13), which highlight the protective role of IL-17A in the IBD.